Coexistence of prothrombic risk factors and its relation to left ventricular thrombus in acute myocardial infarction

Acta Cardiologica

Volumn 59, Issue 1, 2004, Pages 33-39

  Uçar, Fahri ^a   Çelik, Şükrü ^a   Ovali, Ercüment ^a   Karti, S Sami ^a   Pakdemir, Alper ^a   Yilmaz, Mustafa ^a   Önder, Ekin ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

AMI; Factor V Leiden; Gene polymorphism; Left ventricular thrombus; MTHFR; Prothrombin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA HYBRIDIZATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; HEART LEFT VENTRICLE; HEART VENTRICLE THROMBOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ALLELES; FACTOR V; FEMALE; HEART VENTRICLES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; MYOCARDIAL INFARCTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROTHROMBIN; RISK FACTORS; THROMBOSIS;

EID: 1242272118     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.59.1.2005156     Document Type: Article

References (42)

1. Asinger RW, Mikell FL, Elsperger J, Hodges M. Incidence of left ventricular thrombosis after acute transmural myocardial infarction: serial evaluation by two-dimensional echocardiography. N Engl J Med 1981; 305: 297-302.
2. van Dantzig JM, Delemarre BJ, Bot H, Visser CA. Left ventricular thrombus in acute myocardial infarction. Eur Heart J 1996; 17: 1640-5.
3. Weinreich DJ, Burke JF, Pauletto FJ. Left ventricular mural thrombi complicating acute myocardial infarction: long-term follow-up with serial echocardiography. Ann Intern Med 1984; 100: 789-94.
4. Virchow R. Gesammelte Abhandlungen zur wissenchaftlichen Medizin. Frankfurt Meidinger Sohn; 1856: 219-732.
5. Stormorken H, Sakariassen KS. Hemostatic risk factors in arterial thrombosis and atherosclerosis: the thrombin-fibrin and platelet-vWF axis. Thromb Res 1997; 88: 1-25.
6. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary artery disease. Thromb Haemost 1996; 75: 767-71.
7. Gowda MS, Zucker ML, Vacek JL, Carriger WL, Van Laeys DL, Rachel JM, Strope BD. Incidence of factor V Leiden in patients with acute myocardial infarction. J Thromb Thrombolysis 2000; 9: 43-5.
8. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
9. Holm J, Zöller B, Svensson PJ, Berntrop E, Erhardt L, Dahlback B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952.
10. Voetsch B, Damasceno BP, Camargo EC, Massaro A, Bacheschi LA, Scaff M, Annichino-Bizzacchi JM, Arruda VR. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000; 83: 229-33.
11. Çelik S, Ovali E, Baykan M, Uçar F, Erdöl C, Durmus I, Kaplan S. Factor V Leiden and its relation to left ventricular thrombus in acute myocardial infarction. Acta Cardiol 2001; 56: 1-6.
12. Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res 1999; 93(1): 1-8.
13. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88(10): 3698-703.
14. Linfert DR, Tsongalis GJ. Coexistence of the methylenetetrahydrofolate reductase single-nucleotide polymorphism (C677T) in patients with the factor V Leiden or prothrombin G20210A polymorphisms. Diagn Mol Pathol 2001; 10: 111-5.
15. Akar N, Akar E, Misirlioglu M, Avcu F, Yalcin A, Cin S. Search for genetic factors favoring thrombosis in Turkish population. Thromb Res 1998; 92: 79-82.
16. Lopaciuk S, Bykowska K, Kwiecinski H, Mickielewicz A, Czlonkowska A, Mendel T, Kuczynska-Zardzewialy A, Szelagowska D, Windyga J, Schroder W, Herrmann FH, Jedrzejowska H. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost 2001; 7: 346-50.
17. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.
18. Hessner MJ, Dinauer DM, Luhm RA, Endres JL, Montgomery RR, Friedman KD. Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriers. Br J Haematol 1999; 106: 237-9.
19. Akar N, Akar E, Akcay R, Avcu F, Yalcin A, Cin S. Effect of methylenetetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients. Thromb Res 2000; 97: 163-7.
20. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
21. Schiller N, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I et al. Recommendation for quantitation of the left ventricle by two dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-68.
22. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C. Lancet 1995; 345: 526-7.
23. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Mäkelin R, Hämäläinene L, Palomaki H, Kaste M. Arg 506Gln Factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558.
24. Emmerich J, Poirier O, Evans A Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.
25. Van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1995; 1: 185.
26. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
27. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol 1997; 98: 907-9.
28. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 5: 1747-50.
29. Doggen CJM, Manger Cats V, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
30. Kang SS, Wong PWK, Bock HG, Horwitz A, Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 1991; 38: 546-51.
31. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677 to Val in the methylene tetrahydrofolate reducatase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818-21.
32. Salamon O, Dardik R, Zivelin A. Homozygous methylenetetrahydrofolate reductase thermolability (MTHFR-T) is an independent risk factor for idiopathic deep-vein thrombosis (DVT). Thromb Haemost 1997; suppl: 568-569.
33. Alhenc-Gelas M, Arnaud E, Nicaud V, Aubry ML, Fiessinger JN, Aiach M, Emmerich J. Venous thromboembolic disease and the prothrombin, methylenetetrahydrofolate reductase, and factor V genes. Thromb Haemost 1999; 81: 506-10.
34. Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti ML, Bignell M, Mannucci PM. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol 1997; 17: 1662-6.
35. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, den Meijer M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 45-41.
36. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis 1996; 121: 293-4.
37. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6.
38. Verhoef P, Kok FJ, Kluitmans LAJ, Blom HJ, Refsum H, Ueland PM, Kruyssen DACM. The 677CT mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997; 132: 105-13.
39. Anderson JL, King GJ, Thomson MJ, Todd M, Bair T, Muhlestein JB, Carlquist JF. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol 1997; 30: 1206-11.
40. Ilken DEL, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) mutation. Arterioscler Thromb Vasc Biol 1996; 16: 878-82.
41. Visser CA, Kan G, Meltzer RS, Lie KI, Durrer D. Long-term follow-up of left ventricular thrombus after acute myocardial infarction: a two-dimensional echocardiographic study in 96 patients. Chest 1984; 86: 532-6.
42. Domenicucci S, Chiarella F, Bellotti P, Lupi G, Scarsi G, Vecchio C. Early appearance of left ventricular thrombi after anterior myocardial infarction: a marker of higher in-hospital mortality in patients not treated with antithrombotic drugs. Eur Heart J 1990; 11: 51-8.